Robert Owen Hughes - Publications

Affiliations: 
2002 Scripps Research Institute, La Jolla, La Jolla, CA, United States 

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Muegge I, Bentzien J, Mukherjee P, Hughes RO. Automatically updating predictive modeling workflows support decision-making in drug design. Future Medicinal Chemistry. PMID 27584594 DOI: 10.4155/fmc-2016-0070  0.32
2012 Hughes RO, Bartolozzi A, Takahashi H. Inflammatory Targets for the Treatment of Atherosclerosis Annual Reports in Medicinal Chemistry. 47: 223-235. DOI: 10.1016/B978-0-12-396492-2.00015-1  0.32
2011 Xue CB, Wang A, Han Q, Zhang Y, Cao G, Feng H, Huang T, Zheng C, Xia M, Zhang K, Kong L, Glenn J, Anand R, Meloni D, Robinson DJ, ... ... Hughes RO, et al. Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist. Acs Medicinal Chemistry Letters. 2: 913-8. PMID 24900280 DOI: 10.1021/ml200199c  0.32
2011 Hughes RO, Maddux T, Joseph Rogier D, Lu S, Walker JK, Jon Jacobsen E, Rumsey JM, Zheng Y, Macinnes A, Bond BR, Han S. Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. Bioorganic & Medicinal Chemistry Letters. 21: 6348-52. PMID 21955943 DOI: 10.1016/j.bmcl.2011.08.106  0.32
2011 Trujillo JI, Huang W, Hughes RO, Rogier DJ, Turner SR, Devraj R, Morton PA, Xue CB, Chao G, Covington MB, Newton RC, Metcalf B. Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs. Bioorganic & Medicinal Chemistry Letters. 21: 1827-31. PMID 21316220 DOI: 10.1016/j.bmcl.2011.01.052  0.32
2011 Hughes RO, Rogier DJ, Devraj R, Zheng C, Cao G, Feng H, Xia M, Anand R, Xing L, Glenn J, Zhang K, Covington M, Morton PA, Hutzler JM, Davis JW, et al. Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile. Bioorganic & Medicinal Chemistry Letters. 21: 2626-30. PMID 21315584 DOI: 10.1016/j.bmcl.2011.01.034  0.32
2011 Zheng C, Cao G, Xia M, Feng H, Glenn J, Anand R, Zhang K, Huang T, Wang A, Kong L, Li M, Galya L, Hughes RO, Devraj R, Morton PA, et al. Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. Bioorganic & Medicinal Chemistry Letters. 21: 1442-6. PMID 21295478 DOI: 10.1016/j.bmcl.2011.01.015  0.32
2010 Tollefson MB, Acker BA, Jacobsen EJ, Hughes RO, Walker JK, Fox DN, Palmer MJ, Freeman SK, Yu Y, Bond BR. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. Bioorganic & Medicinal Chemistry Letters. 20: 3120-4. PMID 20443228 DOI: 10.1016/j.bmcl.2010.03.111  0.32
2010 Tollefson MB, Acker BA, Jacobsen EJ, Hughes RO, Walker JK, Fox DN, Palmer MJ, Freeman SK, Yu Y, Bond BR. 1-(2-(2,2,2-trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. Bioorganic & Medicinal Chemistry Letters. 20: 3125-8. PMID 20400309 DOI: 10.1016/j.bmcl.2010.03.106  0.32
2010 Hughes RO, Rogier DJ, Jacobsen EJ, Walker JK, Macinnes A, Bond BR, Zhang LL, Yu Y, Zheng Y, Rumsey JM, Walgren JL, Curtiss SW, Fobian YM, Heasley SE, Cubbage JW, et al. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). Journal of Medicinal Chemistry. 53: 2656-60. PMID 20196613 DOI: 10.1021/jm901781q  0.32
2009 Hughes RO, Walker JK, Joseph Rogier D, Heasley SE, Blevis-Bal RM, Benson AG, Jon Jacobsen E, Cubbage JW, Fobian YM, Owen DR, Freskos JN, Molyneaux JM, Brown DL, Acker BA, Maddux TM, et al. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one Bioorganic and Medicinal Chemistry Letters. 19: 5209-5213. PMID 19631533 DOI: 10.1016/j.bmcl.2009.07.019  0.32
2009 Owen DR, Walker JK, Jon Jacobsen E, Freskos JN, Hughes RO, Brown DL, Bell AS, Brown DG, Phillips C, Mischke BV, Molyneaux JM, Fobian YM, Heasley SE, Moon JB, Stallings WC, et al. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 4088-91. PMID 19540112 DOI: 10.1016/j.bmcl.2009.06.012  0.32
2009 Hughes RO, Walker JK, Cubbage JW, Fobian YM, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Owen DR, Jacobsen EJ, Freskos JN, Molyneaux JM, Brown DL, Stallings WC, Acker BA, et al. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system. Bioorganic & Medicinal Chemistry Letters. 19: 4092-6. PMID 19539468 DOI: 10.1016/j.bmcl.2009.06.004  0.32
2002 Nicholas GM, Eckman LL, Ray S, Hughes RO, Pfefferkorn JA, Barluenga S, Nicolaou KC, Bewley CA. Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorganic & Medicinal Chemistry Letters. 12: 2487-90. PMID 12161164 DOI: 10.1016/S0960-894X(02)00385-2  0.32
1998 Li G, Haq W, Xiang L, Lou BS, Hughes R, De Leon IA, Davis P, Gillespie TJ, Romanowski M, Zhu X, Misicka A, Lipkowski AW, Porreca F, Davis TP, Yamamura HI, et al. Modifications of the 4,4'-residues and SAR studies of Biphalin, a highly potent opioid receptor active peptide. Bioorganic & Medicinal Chemistry Letters. 8: 555-60. PMID 9871617 DOI: 10.1016/S0960-894X(98)00065-1  0.32
Show low-probability matches.